Corcept Therapeutics Provides Miricorilant Clinical Development Update
December 08, 2022 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
December 08, 2022 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
November 03, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 27, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update...
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
October 11, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
August 03, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 27, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
June 29, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
June 06, 2022 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update
May 05, 2022 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...